Short and Long Term Effects of Transcatheter Arterial Chemoembolization Combined with Portal Vein 125 Iodine Seed Implantation in the Treatment of Liver Cancer Complicated with Portal Vein Tumor Thrombus
ZHAO Yong-hua, BAI Xue-mei, LIU Ya-min, et al
Department of interventional vascular, Chang'an District Hospital, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710100, Shaanxi
Abstract 【Objective】To investigate the short-term and long-term effect and safety of transcatheter arterial chemoembolization (TACE) combined with portal vein 125 iodine (125I) seed implantation in the treatment of liver cancer complicated with portal vein tumor thrombus (PVTT). 【Methods】 A total of 90 patients with liver cancer complicated with PVTT was randomly divided into control group and observation group. The control group was treated with TACE, and the observation group was treated with TACE combined with portal vein 125I seed implantation. The serological indexes, recurrence rate, survival rate, progression free survival time (PFS) and overall survival time (OS) were compared between the two groups before and after treatment. The short-term efficacy of primary liver tumor and PVTT and the incidence of adverse reactions during treatment were compared between the two groups. 【Results】(1) the remission rate of primary tumor and PVTT in the observation group were significantly higher than those in the control group (P<0.05). (2) After treatment, the serum levels of alpha fetoprotein (AFP) and carcinoembryonic antigen (CEA) in the observation group were lower than those in the control group, and the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL) in the observation group were higher than those in the control group (P<0.05). (3) The 1-year recurrence rate in the observation group was lower than that in the control group (22.2% vs 28.9%, P<0.05), and the 1, 2 and 3-year cumulative survival rates were higher than those in the control group (73.3% vs 57.8%, 44.4% vs 24.4%, 33.3% vs 15.6%, respectively) (P<0.05). The average PFS and OS in the observation group were longer than those in the control group (all P<0.05). (4) There was no significant difference in the incidence of adverse reactions between the two groups during treatment (P>0.05). 【Conclusion 】 TACE combined with 125I seed implantation in portal vein is effective in the treatment of liver cancer complicated with PVTT. It can effectively control the progression of primary tumor and PVTT, prolong the survival time and improve the survival rate, and has good safety.
2021, Vol. 38 
